FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:775-789 February 22, 2007 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Rabe, K. F. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown.

Methods We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 µg plus fluticasone propionate at a dose of 500 µg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years. The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed.

Results Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment. All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone group. The hazard ratio for death in the combination-therapy group, as compared with the placebo group, was 0.825 (95% confidence interval [CI], 0.681 to 1.002; P=0.052, adjusted for the interim analyses), corresponding to a difference of 2.6 percentage points or a reduction in the risk of death of 17.5%. The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantly from that for placebo. As compared with placebo, the combination regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved health status and spirometric values (P<0.001 for all comparisons with placebo). There was no difference in the incidence of ocular or bone side effects. The probability of having pneumonia reported as an adverse event was higher among patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0.001 for comparisons between these treatments and placebo).

Conclusions The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov] .)

Source Information

From University Hospital Aintree, Liverpool, United Kingdom (P.M.A.C.); GlaxoSmithKline Research and Development, Greenford, United Kingdom (J.A.A.); Caritas St. Elizabeth's Medical Center, Boston (B.C.); Pulmonary Research Institute of Southeast Michigan, Livonia (G.T.F.); Woolcock Institute of Medical Research, Sydney (C.J.); St. George's University of London, London (P.W.J.); GlaxoSmithKline Research and Development, Research Triangle Park, NC (J.C.Y.); and Wythenshawe Hospital, Manchester, United Kingdom, and Hvidovre Hospital, Hvidovre, Denmark (J.V.).

Address reprint requests to Dr. Calverley at the Department of Medicine, Clinical Science Centre, University Hospital Aintree, Longmoor Lane, Liverpool L9 7AL, United Kingdom, or at pmacal{at}liverpool.ac.uk.

Full Text of this Article

Related Letters:

Prevention of Death in COPD
Barnes P. J., La Vecchia C., Fabbri L. M., Duerden M., Kupfer Y., Tessler S., Keaney N., Calverley P., Anderson J., Celli B.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:2211-2214, May 24, 2007. Correspondence

Treating COPD
Kiley J. P., Nabel E. G.
Extract | Full Text | PDF  
N Engl J Med 2007; 356:867, Feb 22, 2007. Correspondence

This article has been cited by other articles:

• Celli, B., Decramer, M., Kesten, S., Liu, D., Mehra, S., Tashkin, D. P., on behalf of the UPLIFT Study Investigators, (2009). Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 180: 948-955 [Abstract] [Full Text]  
• Keene, O. N., Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W. (2009). Methods for therapeutic trials in COPD: lessons from the TORCH trial. Eur Respir J 34: 1018-1023 [Abstract] [Full Text]  
• Vestbo, J, Anderson, J A, Calverley, P M A, Celli, B, Ferguson, G T, Jenkins, C, Knobil, K, Willits, L R, Yates, J C, Jones, P W (2009). Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 64: 939-943 [Abstract] [Full Text]  
• Lapperre, T. S., Snoeck-Stroband, J. B., Gosman, M. M.E., Jansen, D. F., van Schadewijk, A., Thiadens, H. A., Vonk, J. M., Boezen, H. M., ten Hacken, N. H.T., Sont, J. K., Rabe, K. F., Kerstjens, H. A.M., Hiemstra, P. S., Timens, W., Postma, D. S., Sterk, P. J., the GLUCOLD (Groningen Leiden Universities Cortico, (2009). Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease: A Randomized Trial. ANN INTERN MED 151: 517-527 [Abstract] [Full Text]  
• Jones, P. W. (2009). Triple Therapy for Chronic Obstructive Pulmonary Disease: Trials Catching Up with Clinical Practice?. Am. J. Respir. Crit. Care Med. 180: 689-690 [Full Text]  
• Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., Kessler, R. (2009). Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 180: 741-750 [Abstract] [Full Text]  
• McWilliams, J. M., Meara, E., Zaslavsky, A. M., Ayanian, J. Z. (2009). Medicare Spending for Previously Uninsured Adults. ANN INTERN MED 0: 0000605-200912010-00149v1-E-149 [Abstract] [Full Text]  
• Black, J. L., Oliver, B. G. G., Roth, M. (2009). Molecular Mechanisms of Combination Therapy With Inhaled Corticosteroids and Long-Acting {beta}-Agonists. Chest 136: 1095-1100 [Abstract] [Full Text]  
• Barnes, P. J. (2009). Histone deacetylase-2 and airway disease. Ther Adv Respir Dis 3: 235-243 [Abstract]  
• Rodrigo, G. J., Castro-Rodriguez, J. A., Plaza, V. (2009). Safety and Efficacy of Combined Long-Acting {beta}-Agonists and Inhaled Corticosteroids vs Long-Acting {beta}-Agonists Monotherapy for Stable COPD: A Systematic Review. Chest 136: 1029-1038 [Abstract] [Full Text]  
• Sin, D. D., Vestbo, J. (2009). Biomarkers in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 6: 543-545 [Abstract] [Full Text]  
• Maclay, J. D., McAllister, D. A., Mills, N. L., Paterson, F. P., Ludlam, C. A., Drost, E. M., Newby, D. E., MacNee, W. (2009). Vascular Dysfunction in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 180: 513-520 [Abstract] [Full Text]  
• Puhan, M. A., Schunemann, H. J. (2009). How to increase the value of randomised trials in COPD research. Eur Respir J 34: 552-558 [Abstract] [Full Text]  
• Effing, T. W., Kerstjens, H. A. M., Monninkhof, E. M., van der Valk, P. D. L. P. M., Wouters, E. F. M., Postma, D. S., Zielhuis, G. A., van der Palen, J. (2009). Definitions of Exacerbations: Does It Really Matter in Clinical Trials on COPD?. Chest 136: 918-923 [Abstract] [Full Text]  
• Crim, C., Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Willits, L. R., Yates, J. C., Vestbo, J. (2009). Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34: 641-647 [Abstract] [Full Text]  
• MacDonald, M., Bardin, P. (2009). "Temporal Clustering" of COPD Exacerbations May Reflect Corticosteroid Withdrawal. Am. J. Respir. Crit. Care Med. 180: 482-483 [Full Text]  
• Phung, O. J, White, C M., Baker, W. L, Coleman, C. I (2009). Assessing the Usefulness of Health-Related Quality-of-Life Trials: A Clinician's Perspective Using Two COPD Examples. The Annals of Pharmacotherapy 43: 1496-1505 [Abstract] [Full Text]  
• Emami, K., Stephen, M., Kadlecek, S., Cadman, R. V., Ishii, M., Rizi, R. R. (2009). Quantitative Assessment of Lung Using Hyperpolarized Magnetic Resonance Imaging. Proc Am Thorac Soc 6: 431-438 [Abstract] [Full Text]  
• Lee, T. A., Wilke, C., Joo, M., Stroupe, K. T., Krishnan, J. A., Schumock, G. T., Pickard, A. S. (2009). Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 169: 1403-1410 [Abstract] [Full Text]  
• Bridevaux, P-O., Gerbase, M. W., Schindler, C., Felber Dietrich, D., Curjuric, I., Dratva, J., Ackermann-Liebrich, U., Probst-Hensch, N. M., Gaspoz, J-M., Rochat, T. (2009). Sex-specific effect of body weight gain on systemic inflammation in subjects with COPD: results from the SAPALDIA cohort study 2. Eur Respir J 34: 332-339 [Abstract] [Full Text]  
• Partridge, M. R., Schuermann, W., Beckman, O., Persson, T., Polanowski, T. (2009). Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 3: 147-157 [Abstract]  
• Broekhuizen, B. D., Sachs, A. P., Oostvogels, R., Hoes, A. W, Verheij, T. J., Moons, K. G. (2009). The diagnostic value of history and physical examination for COPD in suspected or known cases: a systematic review. Fam Pract 26: 260-268 [Abstract] [Full Text]  
• Young, R P, Hopkins, R, Eaton, T E (2009). Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 85: 414-421 [Abstract] [Full Text]  
• Postma, D. S., Calverley, P. (2009). Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 34: 10-12 [Full Text]  
• Suissa, S., Barnes, P. J. (2009). Inhaled corticosteroids in COPD: the case against. Eur Respir J 34: 13-16 [Full Text]  
• Brusselle, G. G., Demoor, T., Bracke, K. R., Brandsma, C-A., Timens, W. (2009). Lymphoid follicles in (very) severe COPD: beneficial or harmful?. Eur Respir J 34: 219-230 [Abstract] [Full Text]  
• de Oca, M. M., Talamo, C., Halbert, R. J., Perez-Padilla, R., Lopez, M. V., Muino, A., Jardim, J. R. B., Valdivia, G., Pertuze, J., Moreno, D., Menezes, A. M. B. (2009). Frequency of Self-Reported COPD Exacerbation and Airflow Obstruction in Five Latin American Cities: The Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) Study. Chest 136: 71-78 [Abstract] [Full Text]  
• Elliott, M. W (2009). Domiciliary non-invasive ventilation in stable COPD?. Thorax 64: 553-556 [Full Text]  
• Hawkins, N. M., MacDonald, M. R., Petrie, M. C., Chalmers, G. W., Carter, R., Dunn, F. G., McMurray, J. J.V. (2009). Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 11: 684-690 [Abstract] [Full Text]  
• Barnes, P. J., Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165-1185 [Abstract] [Full Text]  
• Janssens, W., Lehouck, A., Carremans, C., Bouillon, R., Mathieu, C., Decramer, M. (2009). Vitamin D Beyond Bones in Chronic Obstructive Pulmonary Disease: Time to Act. Am. J. Respir. Crit. Care Med. 179: 630-636 [Abstract] [Full Text]  
• Gaschler, G. J., Skrtic, M., Zavitz, C. C. J., Lindahl, M., Onnervik, P.-O., Murphy, T. F., Sethi, S., Stampfli, M. R. (2009). Bacteria Challenge in Smoke-exposed Mice Exacerbates Inflammation and Skews the Inflammatory Profile. Am. J. Respir. Crit. Care Med. 179: 666-675 [Abstract] [Full Text]  
• Drummond, M. B., Fan, E. (2009). Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease--Reply. JAMA 301: 1433-1434 [Full Text]  
• Perng, D-W., Tao, C-W., Su, K-C., Tsai, C-C., Liu, L-Y., Lee, Y-C. (2009). Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 33: 778-784 [Abstract] [Full Text]  
• Cazzola, M., Noschese, P., Di Perna, F. (2009). Value of adding a polyvalent mechanical bacterial lysate to therapy of COPD patients under regular treatment with salmeterol/fluticasone. Ther Adv Respir Dis 3: 59-63 [Abstract]  
• Dal Negro, R. W., Bonadiman, L., Turati, C., Turco, P. (2009). Clinical and pharmacoeconomic profile of COPD patients with FEV1 50--60% predicted: pilot study on the impact of the extended indication of ICS/LABA. Ther Adv Respir Dis 3: 51-58 [Abstract]  
• Suissa, S., Ernst, P. (2009). How Much Did Biases in the Study of Chronic Obstructive Pulmonary Disease Medications and Mortality Affect the Outcome?. ANN INTERN MED 150: 425-426 [Full Text]  
• Keene, O. N., Celli, B., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., Vestbo, J., Knobil, K., Yates, J. C., Calverley, P. M. A. (2009). Lung function decline in COPD trials. Eur Respir J 33: 708-709 [Full Text]  
• Suissa, S. (2009). From the authors. Eur Respir J 33: 709-710 [Full Text]  
• Aaron, S. D. (2009). COPD Exacerbations: Predicting the Future from the Recent Past. Am. J. Respir. Crit. Care Med. 179: 335-336 [Full Text]  
• Marchand, E. (2009). Effect of Pharmacotherapy on Rate of Decline of FEV1 in the TORCH Study. Am. J. Respir. Crit. Care Med. 179: 426-426 [Full Text]  
• Celli, B. R., for the TORCH study members, (2009). Effect of Pharmacotherapy on Rate of Decline of FEV1 in the TORCH Study. Am. J. Respir. Crit. Care Med. 179: 426-427 [Full Text]  
• Hawkins, N. M., Huang, Z., Pieper, K. S., Solomon, S. D., Kober, L., Velazquez, E. J., Swedberg, K., Pfeffer, M. A., McMurray, J. J.V., Maggioni, A. P., for the Valsartan in Acute Myocardial Infarction T, (2009). Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 11: 292-298 [Abstract] [Full Text]  
• Black, P N, McDonald, C F (2009). Interventions to reduce the frequency of exacerbations of chronic obstructive pulmonary disease. Postgrad. Med. J. 85: 141-147 [Abstract] [Full Text]  
• Singh, S., Amin, A. V., Loke, Y. K. (2009). Long-term Use of Inhaled Corticosteroids and the Risk of Pneumonia in Chronic Obstructive Pulmonary Disease: A Meta-analysis. Arch Intern Med 169: 219-229 [Abstract] [Full Text]  
• Kardos, P. (2009). Methodological issues in therapeutic trials of COPD. Eur Respir J 33: 443-444 [Full Text]  
• Suissa, S. (2009). Statistical methods in pharmacoepidemiology: advances and challenges. Stat Methods Med Res 18: 3-6  
• Cazzola, M. (2009). From large clinical trials to management of COPD in the real world. Ther Adv Respir Dis 3: 39-46 [Abstract]  
• Decramer, M., Molenberghs, G. (2009). Does Pharmacotherapy Reduce the Rate of Decline of Lung Function in COPD?. Am. J. Respir. Crit. Care Med. 179: 171-171 [Full Text]  
• Sin, D. D., Paul Man, S. F. (2009). Systemic Inflammation and Inhaled Corticosteroids in COPD. Am. J. Respir. Crit. Care Med. 179: 170-171 [Full Text]  
• Pinnock, H. (2009). A woman attending for routine review of her chronic obstructive pulmonary disease. BMJ 338: b70-b70 [Full Text]  
• Busacker, A., Newell, J. D. Jr, Keefe, T., Hoffman, E. A., Granroth, J. C., Castro, M., Fain, S., Wenzel, S. (2009). A Multivariate Analysis of Risk Factors for the Air-Trapping Asthmatic Phenotype as Measured by Quantitative CT Analysis. Chest 135: 48-56 [Abstract] [Full Text]  
• Iwamoto, H., Yokoyama, A., Kitahara, Y., Ishikawa, N., Haruta, Y., Yamane, K., Hattori, N., Hara, H., Kohno, N. (2009). Airflow Limitation in Smokers Is Associated with Subclinical Atherosclerosis. Am. J. Respir. Crit. Care Med. 179: 35-40 [Abstract] [Full Text]  
• MacNee, W., Maclay, J., McAllister, D. (2008). Cardiovascular Injury and Repair in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 5: 824-833 [Abstract] [Full Text]  
• Rodriguez-Roisin, R., Soriano, J. B. (2008). Chronic Obstructive Pulmonary Disease with Lung Cancer and/or Cardiovascular Disease. Proc Am Thorac Soc 5: 842-847 [Abstract] [Full Text]  
• Luppi, F., Franco, F., Beghe, B., Fabbri, L. M. (2008). Treatment of Chronic Obstructive Pulmonary Disease and Its Comorbidities. Proc Am Thorac Soc 5: 848-856 [Abstract] [Full Text]  
• Barnes, P. J. (2008). Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities. Proc Am Thorac Soc 5: 857-864 [Abstract] [Full Text]  
• Barnes, P. J. (2008). Emerging Pharmacotherapies for COPD. Chest 134: 1278-1286 [Abstract] [Full Text]  
• Seemungal, T. A. R., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., Sapsford, R. J., Wedzicha, J. A. (2008). Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. Am. J. Respir. Crit. Care Med. 178: 1139-1147 [Abstract] [Full Text]  
• Drummond, M. B., Dasenbrook, E. C., Pitz, M. W., Murphy, D. J., Fan, E. (2008). Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA 300: 2407-2416 [Abstract] [Full Text]  
• Suissa, S. (2008). Methodologic Shortcomings of the INSPIRE Randomized Trial. Am. J. Respir. Crit. Care Med. 178: 1090-1091 [Full Text]  
• Barbier, M., Agusti, A., Alberti, S. (2008). Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 32: 1283-1288 [Abstract] [Full Text]  
• Wedzicha, J. A (2008). Antibiotics at COPD exacerbations: the debate continues. Thorax 63: 940-942 [Full Text]  
• Gross, N. J. (2008). Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation. Mayo Clin Proc. 83: 1241-1250 [Abstract] [Full Text]  
• Reilly, J. J. (2008). COPD and Declining FEV1 -- Time to Divide and Conquer?. NEJM 359: 1616-1618 [Full Text]  
• Godtfredsen, N. S., Lam, T. H., Hansel, T. T., Leon, M. E., Gray, N., Dresler, C., Burns, D. M., Prescott, E., Vestbo, J. (2008). COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 32: 844-853 [Abstract] [Full Text]  
• Suissa, S. (2008). Exacerbations and intent-to-treat analyses in randomised trials. Eur Respir J 32: 1117-1118 [Full Text]  
• Singh, S., Loke, Y. K., Furberg, C. D. (2008). Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA 300: 1439-1450 [Abstract] [Full Text]  
• Aaron, S. D. MD, Fergusson, D. A. PhD (2008). Exaggeration of treatment benefits using the "event-based" number needed to treat. CMAJ 179: 669-671 [Full Text]  
• Lee, T. A., Pickard, A. S., Au, D. H., Bartle, B., Weiss, K. B. (2008). Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease. ANN INTERN MED 149: 380-390 [Abstract] [Full Text]  
• Rennard, S. I., Vestbo, J. (2008). The Many "Small COPDs": COPD Should Be an Orphan Disease. Chest 134: 623-627 [Abstract] [Full Text]  
• Curtis, J. R. (2008). Palliative and end-of-life care for patients with severe COPD. Eur Respir J 32: 796-803 [Abstract] [Full Text]  
• Camargo, C. A. Jr, Barr, R. G., Chen, R., Speizer, F. E. (2008). Prospective Study of Inhaled Corticosteroid Use, Cardiovascular Mortality, and All-Cause Mortality in Asthmatic Women. Chest 134: 546-551 [Abstract] [Full Text]  
• Martinez, F. J., Han, M. K., Andrei, A.-C., Wise, R., Murray, S., Curtis, J. L., Sternberg, A., Criner, G., Gay, S. E., Reilly, J., Make, B., Ries, A. L., Sciurba, F., Weinmann, G., Mosenifar, Z., DeCamp, M., Fishman, A. P., Celli, B. R., for the National Emphysema Treatment Trial Researc, (2008). Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema. Am. J. Respir. Crit. Care Med. 178: 491-499 [Abstract] [Full Text]  
• Wijesinghe, M, Perrin, K, Harwood, M, Weatherall, M, Beasley, R (2008). The risk of asthma mortality with inhaled long acting {beta}-agonists. Postgrad. Med. J. 84: 467-472 [Abstract] [Full Text]  
• Stockl, K. M., Le, L., Harada, A. S. M., Zhang, S. (2008). Use of controller medications in patients initiated on a long-acting {beta}2-adrenergic agonist before and after safety alerts. Am J Health Syst Pharm 65: 1533-1538 [Abstract] [Full Text]  
• Suissa, S. (2008). Medications to Modify Lung Function Decline in Chronic Obstructive Pulmonary Disease: Some Hopeful Signs. Am. J. Respir. Crit. Care Med. 178: 322-323 [Full Text]  
• Celli, B. R., Thomas, N. E., Anderson, J. A., Ferguson, G. T., Jenkins, C. R., Jones, P. W., Vestbo, J., Knobil, K., Yates, J. C., Calverley, P. M. A. (2008). Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH Study. Am. J. Respir. Crit. Care Med. 178: 332-338 [Abstract] [Full Text]  
• Cooper, C. B., Decramer, M. (2008). Inhaled steroids and COPD. Eur Respir J 32: 523-524 [Full Text]  
• Donohue, J. F., Hanania, N. A., Fogarty, C., Campbell, S. C., Rinehart, M., Denis-Mize, K. (2008). Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial. Ther Adv Respir Dis 2: 199-208 [Abstract]  
• Cazzola, M., Matera, M. G. (2008). To Add, or Not To Add an Inhaled Corticosteroid in Moderate COPD: That Is the Question. Chest 134: 223-225 [Full Text]  
• Rabe, K. F., Timmer, W., Sagkriotis, A., Viel, K. (2008). Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD. Chest 134: 255-262 [Abstract] [Full Text]  
• Stolz, D., Christ-Crain, M., Morgenthaler, N. G., Miedinger, D., Leuppi, J., Muller, C., Bingisser, R., Struck, J., Muller, B., Tamm, M. (2008). Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD. Chest 134: 263-272 [Abstract] [Full Text]  
• Keene, O. N., Calverley, P. M. A., Jones, P. W., Vestbo, J., Anderson, J. A. (2008). Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. Eur Respir J 32: 17-24 [Abstract] [Full Text]  
• Mendes, E. S., Horvath, G., Rebolledo, P., Monzon, M. E., Casalino-Matsuda, S. M., Wanner, A. (2008). Effect of an inhaled glucocorticoid on endothelial function in healthy smokers. J. Appl. Physiol. 105: 54-57 [Abstract] [Full Text]  
• Gillissen, A. (2008). Is Salmeterol/Fluticasone Propionate Equivalent to Tiotropium Bromide in the Treatment of COPD?. Am. J. Respir. Crit. Care Med. 178: 105-105 [Full Text]  
• Middleton, P. G. (2008). Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. Am. J. Respir. Crit. Care Med. 178: 106-106 [Full Text]  
• Benfield, T., Lange, P., Vestbo, J. (2008). COPD Stage and Risk of Hospitalization for Infectious Disease. Chest 134: 46-53 [Abstract] [Full Text]  
• Wedzicha, J. A., Calverley, P. M. A., Seemungal, T. A., Hagan, G., Ansari, Z., Stockley, R. A., for the INSPIRE Investigators, (2008). Management of Patients with COPD: A Comparison of the INSPIRE and TORCH Studies. Am. J. Respir. Crit. Care Med. 178: 106-107 [Full Text]  
• Singh, D, Brooks, J, Hagan, G, Cahn, A, O'Connor, B J (2008). Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63: 592-598 [Abstract] [Full Text]  
• Shafazand, S. (2008). Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD. Evid. Based Med. 13: 74-74 [Full Text]  
• Chung, K. F., Adcock, I. M. (2008). Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 31: 1334-1356 [Abstract] [Full Text]  
• Celli, B. R. (2008). Update on the Management of COPD. Chest 133: 1451-1462 [Abstract] [Full Text]  
• Almirall, J., Bolibar, I., Serra-Prat, M., Roig, J., Hospital, I., Carandell, E., Agusti, M., Ayuso, P., Estela, A., Torres, A., the Community-Acquired Pneumonia in Catalan Countr, (2008). New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31: 1274-1284 [Abstract] [Full Text]